Europe Biotechnology and Genetic Engineering Market Size, Share & Trends Analysis Report By Application Type (Therapeutic Biotech {62.0%}, Agricultural Biotech {20.0%}, Industrial Biotech {12.0%}, Research Tools {6.0%}), By Technology Platform (Gene Therapy/CRISPR {38.0%}, mRNA Therapeutics {28.0%}, Monoclonal Antibodies {18.0%}, Other Platforms {16.0%}), By Disease Focus (Oncology {35.0%}, Rare Genetic Diseases {22.0%}, Infectious Diseases {18.0%}, Cardiovascular {15.0%}, Other {10.0%}), By Development Stage (Clinical Programs {45.0%}, Marketed Products {38.0%}, Preclinical {17.0%}), By Region (United Kingdom {28.0%}, Germany {24.0%}, France {18.0%}, Switzerland {15.0%}, Nordic & Belgium {15.0%}) - Forecasts, 2026-2034

Table of Content

1. Introduction

1.1. Market Introduction

1.2. Executive Summary

1.3. Market Scope & Overview

1.4. Market Research Methodology

1.5. Market Estimation Methodology

1.6. Product Overview of Biotechnology and Genetic Engineering

1.7. Europe Biotechnology and Genetic Engineering Market: Classification

1.8. Geographic Scope

1.9. Years Considered for the Study

2. Market Dynamics

2.1. Drivers

2.1.1. Precision Medicine and Genetic Therapeutics Addressing Previously Untreatable Diseases

2.1.2. Agricultural Productivity and Sustainable Food Production Driving Biotech Crop Development

2.2. Restraints

2.2.1. Complex Regulatory Frameworks and Public Perception Challenges

2.3. Opportunities

2.3.1. mRNA Therapeutics Platform Expansion Beyond Infectious Diseases

2.3.2. mRNA Cancer Therapy Development

2.3.3. mRNA Cardiovascular and Metabolic Disease Therapy

2.3.4. Advanced mRNA Manufacturing Capacity Expansion

2.3.5. Combination of Therapies and Platform Integration

3. Europe Biotechnology and Genetic Engineering Market Segmentation, Revenue (USD Billion), (2025–2034)

3.1. By Application Type

3.1.1. Therapeutic Biotechnology

3.1.2. Agricultural Biotechnology

3.1.3. Industrial Biotechnology

3.1.4. Research Tools and Diagnostics

3.2. By Technology Platform

3.2.1. Gene Therapy and Genetic Modification (CRISPR, Viral Vectors)

3.2.2. mRNA Therapeutics

3.2.3. Monoclonal Antibodies

3.2.4. Other Platforms (Synthetic Biology, Protein Engineering, Cell Therapy)

3.3. By Disease Focus

3.3.1. Oncology

3.3.2. Rare Genetic Diseases

3.3.3. Infectious Diseases

3.3.4. Cardiovascular and Metabolic Diseases

3.3.5. Other Therapeutic Areas

3.4. By Development Stage

3.4.1. Clinical-Stage Programs

3.4.2. Marketed Products

3.4.3. Preclinical and Early-Stage Programs

4. Europe Biotechnology and Genetic Engineering Market Overview, By Region

4.1. Western Europe

4.1.1. United Kingdom

4.1.2. Germany

4.1.3. France

4.1.4. Switzerland

4.2. Northern Europe & Benelux

4.2.1. Sweden

4.2.2. Denmark

4.2.3. Norway

4.2.4. Finland

4.2.5. Belgium

4.3. Southern Europe

4.3.1. Spain

4.3.2. Italy

4.3.3. Portugal

4.3.4. Greece

4.4. Eastern Europe

4.4.1. Poland

4.4.2. Czech Republic

4.4.3. Hungary

4.4.4. Romania

5. Europe Biotechnology and Genetic Engineering Market Revenue: Competitive Analysis, 2025

5.1. Key Strategies by Market Players

5.2. Revenue and Market Share Analysis

5.3. Strategic Positioning of Companies

5.4. Investment and Funding Landscape

6. Competitive Landscape

6.1. BioNTech

6.2. CureVac

6.3. Genmab

6.4. Arcturus Therapeutics

6.5. Moderna

6.6. Roche

6.7. Novartis

6.8. Sanofi

6.9. Merck KGaA

6.10. Vertex Pharmaceuticals

7. Recent Industry Developments

7.1. European Medicines Agency Biotech Approval Acceleration

7.2. BioNTech mRNA Cancer Therapy Programs

7.3. UK Government Life Sciences Investment Initiatives

7.4. German Biotech Manufacturing Expansion

7.5. CRISPR Crop Commercialization in Europe

7.6. EU Horizon Europe Biotech Funding Programs

8. Market Research Findings & Conclusion

9. Frequently Asked Questions (FAQs)

10. Disclaime